The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Open accessAbstract
Breast carcinomas are often infiltrated by inflammatory cells, particularly macrophages and T lymphocytes, but the significance of these cells remains unclear. One possible role of these inflammatory cells is that they represent a cell-mediated immune response against the carcinoma. CD8+lymphocytes are a known crucial component of cell-mediated immunity. The purpose of this study was to explore the prognostic value of tumor-infiltrating CD8+cytotoxic lymphocytes in breast cancer. Tumor-infiltrating CD8+lymphocytes were assessed by immunohistochemical staining of tissue microarray cores from 1,334 unselected breast tumors from patients with long-term follow-up. The number of CD8+T cells was counted in tumor nests (intratumoral), in stroma adjacent to tumor cells, and in stroma distant to tumor cells, and their relationship with clinical outcome was determined. The total number of CD8+cells was positively correlated with tumor grade (r s= 0.20; P < .001) and inversely correlated with patient's age at diagnosis, estrogen receptor–alpha (ER-α), and progesterone receptor (PgR) expression (Mann-Whitney U test, P < .001). The total patient cohort was randomly divided into two separate training and validation sets before performing univariate survival analysis. Total number and distant stromal CD8+lymphocytes were associated with better patient survival (P = .041 and P < .001, respectively) in the training set. In multivariate analysis, total CD8+T-cell count was an independent prognostic factor in both training and validation sets. These results suggest that tumor-infiltrating CD8+T lymphocytes have antitumor activity as judged by their favorable effect on patients' survival and could potentially be exploited in the treatment of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Self-citationCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Prognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O. (2007) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,283
Self-citationTumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
The Nottingham prognostic index in primary breast cancer
Galea, M. H., Blamey, R. W., Elston, C. E., & Ellis, I. O. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01840834 · Cited by 1,070
Self-citationIn Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 954
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Validation of Tissue Microarray Technology in Breast Carcinoma
Camp, R. L., Charette, L. A., & Rimm, D. L. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780204 · Cited by 799
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639
Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O. (2005) · International Journal of Cancer · doi:10.1002/ijc.21004 · Cited by 606
Self-citationExpression of luminal and basal cytokeratins in human breast carcinoma
Abd El‐Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J., Blamey, R., Robertson, J. F., Nicholson, R. I., & Ellis, I. O. (2004) · The Journal of Pathology · doi:10.1002/path.1559 · Cited by 594
Self-citationFukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., et al. (2004) · Pancreas · doi:10.1097/00006676-200401000-00023 · Cited by 532
Molecular evolution of breast cancer
Simpson, P. T., Reis‐Filho, J. S., Gale, T., & Lakhani, S. R. (2005) · The Journal of Pathology · doi:10.1002/path.1691 · Cited by 517
ELLIS, I. O., GALEA, M., BROUGHTON, N., LOCKER, A., BLAMEY, R. W., & ELSTON, C. W. (1992) · Histopathology · doi:10.1111/j.1365-2559.1992.tb01032.x · Cited by 487
Self-citationDecreased antigen presentation by dendritic cells in patients with breast cancer.
Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D., & Carbone, D. P. (1997) · PubMed · Cited by 429
Kawai, O., Ishii, G., Kubota, K., Murata, Y., Naito, Y., Mizuno, T., Aokage, K., Saijo, N., Nishiwaki, Y., Gemma, A., et al. (2008) · Cancer · doi:10.1002/cncr.23712 · Cited by 384
Rakha, E., Putti, T., Abd El‐Rehim, D., Paish, C., Green, A., Powe, D., Lee, A., Robertson, J., & Ellis, I. (2006) · The Journal of Pathology · doi:10.1002/path.1916 · Cited by 311
Self-citationCancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?
Bui, J. D., & Schreiber, R. D. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.001 · Cited by 303
PINDER, S. E., ELLIS, I. O., GALEA, M., O'ROUKE, S., BLAMEY, R. W., & ELSTON, C. W. (1994) · Histopathology · doi:10.1111/j.1365-2559.1994.tb01269.x · Cited by 287
Self-citationLymphocyte infiltrates as a prognostic variable in female breast cancer
Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V.-M., Marin, S., Alhava, E., & Syrjänen, K. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90134-n · Cited by 286
Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance
Rakha, E. A., El-Rehim, D. A., Paish, C., Green, A. R., Lee, A. H. S., Robertson, J. F., Blamey, R. W., Macmillan, D., & Ellis, I. O. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.08.015 · Cited by 193
Self-citationMarrogi, A. J., Munshi, A., Merogi, A. J., Ohadike, Y., El-Habashi, A., Marrogi, O. L., & Freeman, S. M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971021)74:5<492::aid-ijc3>3.0.co;2-z · Cited by 183
An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0987-8 · Cited by 180
Self-citationDolled-Filhart, M., McCabe, A., Giltnane, J., Cregger, M., Camp, R. L., & Rimm, D. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0100 · Cited by 180
Expression of BRCA1 protein in breast cancer and its prognostic significance
Rakha, E. A., Elsheikh, S. E., Kandil, M. A. E.-H., El‐Sayed, M. E., Green, A. R., & Ellis, I. O. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.10.011 · Cited by 170
Self-citationGao, G. F., & Jakobsen, B. K. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01750-3 · Cited by 162
Shimokawara, I., Imamura, M., Yamanaka, N., Ishii, Y., & Kikuchi, K. (1982) · Cancer · Cited by 140
Review Article The immunology and immunotherapy of breast cancer: an update
Hadden, J. W. (1999) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(98)00077-0 · Cited by 122
Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer
Baxevanis, C. N., Dedoussis, G. V., Papadopoulos, N. G., Missitzis, I. L., Stathopoulos, G. P., & Papamichail, M. (1994) · Cancer · doi:10.1002/1097-0142(19940815)74:4<1275::aid-cncr2820740416>3.0.co;2-q · Cited by 112
Angiogenesis and inflammation in invasive carcinoma of the breast.
Lee, A. H., Happerfield, L. C., Bobrow, L. G., & Millis, R. R. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.8.669 · Cited by 95
Self-citationDifferent patterns of inflammation and prognosis in invasive carcinoma of the breast
Lee, A. H. S., Gillett, C., Ryder, K., Fentiman, I. S., Miles, D. W., & Millis, R. R. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02410.x · Cited by 88
Self-citationGeorgiannos, S. N., Renaut, A., Goode, A. W., & Sheaff, M. T. (2003) · Surgery · doi:10.1016/s0039-6060(03)00292-7 · Cited by 66
McCoy, J. L., Rucker, R., & Petros, J. A. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006405504158 · Cited by 57
Biological markers and breast cancer. A multiparametric study. II: Depressed immune competence
Mandeville, R., Lamoureux, G., Legault-Poisson, S., & POISSON, R. (1982) · Cancer · doi:10.1002/1097-0142(19821001)50:7<1280::aid-cncr2820500710>3.0.co;2-2 · Cited by 48
Ashida, A., Boku, N., Aoyagi, K., Sato, H., Tsubosa, Y., Minashi, K., Muto, M., Ohtsu, A., Ochiai, A., Yoshida, T., et al. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.6.1345 · Cited by 46
Quantifying tumour-infiltrating lymphocyte subsets: A practical immuno-histochemical method
Loughlin, P., Cooke, T. G., George, W. D., Gray, A. J., Stott, D. I., & Going, J. J. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.01.012 · Cited by 29
Manjili, M. H., Arnouk, H., Knutson, K. L., Kmieciak, M., Disis, M. L., Subjeck, J. R., & Kazim, A. L. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9044-4 · Cited by 26
Augmenting the Potency of Breast Cancer Vaccines: Combined Modality Immunotherapy
Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2004) · Breast Disease · doi:10.3233/bd-2004-20103 · Cited by 20
Cited by
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citationThe immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Metadata
- Authors
- Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-20
- Volume
- 29
- Issue
- 15
- Pages
- 1949-1955
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120338564
- Cited by
- 1,367
- References
- 50
- FWCI
- 20.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.